4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a U.S. clinical-stage genetic medicines company developing adeno-associated virus (AAV) vector-based therapies designed for durable, disease-targeted expression after a single administration. Its near-term value is concentrated in 4D-150, an intravitreal gene therapy candidate for retinal vascular diseases (wet AMD and DME) that uses an R100 vector and a transgene cassette encoding aflibercept plus an inhibitory miRNA targeting VEGF-C. A second prioritized program, 4D-710, targets cystic fibrosis by delivering the CFTR transgene to the lung and is being advanced through the AEROW clinical trial. The company funds operations primarily through equity financings and, to a lesser extent, collaboration and license arrangements, including an APAC partnership with Otsuka for 4D-150.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueIntravitreal AAV gene therapy programs for retinal vascular diseases, led by 4D-150 in wet AMD and DME.
Inhaled/lung-delivered genetic medicine programs focused on cystic fibrosis via CFTR transgene delivery.
Non-prioritized clinical-stage programs intended for partnering or other strategic alternatives across GA, AATD, and Fabry cardiomyopathy.
AAV capsid/vector platform capabilities and monetization via collaboration, licensing, milestones and royalties.
Customers
As a pre-commercial biotechnology company, 4D Molecular Therapeutics’ near-term “customers” are primarily partners and funding counterparties that provide upfront payments, cost sharing, milestones, and potential royalties tied to development and commercialization outcomes. The Otsuka collaboration makes Otsuka a key customer-like counterparty for 4D-150 in Japan, China, Australia and other APAC markets, while 4DMT retains rights outside APAC. Disease-area stakeholders—retina specialists, pulmonologists, hospitals/infusion or procedure sites, and payors—are the ultimate downstream adopters if products are approved, with adoption driven by durability, safety, and reduction in treatment burden versus established therapies. Clinical trial sites and investigators are also critical operational “customers” in the sense that enrollment and execution determine timelines and data quality. Over time, the business model is expected to shift toward product sales (outside partnered territories) plus royalties in partnered regions.
License rights to develop/commercialize programs in specific territories (e.g., 4D-150 in APAC) in exchange for upfront cash, cost sharing, milestones and royalties.
Provide program-specific funding (e.g., CF Foundation support for AEROW Phase 2 start, redosing and Phase 3 readiness) to accelerate development and de-risk trials.
Would adopt 4D-150 if approved to reduce injection frequency and maintain vision outcomes with sustained intraocular anti-VEGF expression.
Would use 4D-710 if approved to address CFTR deficiency with durable lung expression and potential functional improvements.
Strategy
Management’s stated direction is a pipeline prioritization that concentrates resources on 4D-150 (retinal vascular diseases) and 4D-710 (cystic fibrosis) to maximize probability-adjusted value and streamline execution. For other clinical-stage assets (4D-175, 4D-725, 4D-310), the company is pursuing strategic alternatives such as partnering, while discontinuing certain ophthalmology programs (4D-110 and 4D-125). The Otsuka agreement for APAC rights to 4D-150 provides non-dilutive capital, potential milestones, and a commercialization pathway in key Asian markets while 4DMT continues to lead global Phase 3 development. For 4D-710, the CF Foundation funding supports progression into Phase 2 activities, redosing, and Phase 3 readiness work, aiming to accelerate clinical proof-of-concept and regulatory path clarity.
Late-stage data and regulatory submissions are the main catalysts for value creation and future commercialization outside partnered territories.
Demonstrating durable CFTR expression and clinical benefit would differentiate the program and support partnering or pivotal development.
Partnerships can extend runway and preserve optionality while focusing internal resources on the two priority programs.
Geography
Q1/20264D Molecular Therapeutics is headquartered in the United States and runs clinical development across multiple geographies through global trial execution and third-party vendors. The 4FRONT-2 Phase 3 trial for wet AMD is described as global, implying multi-region enrollment and regulatory coordination. Commercial rights for 4D-150 are split by territory: Otsuka holds exclusive rights in Japan, China, Australia and other APAC markets, while 4DMT retains rights in the U.S., Europe and Latin America. This footprint creates region-specific regulatory, reimbursement, and partner-execution dependencies, particularly in APAC where commercialization is delegated to Otsuka. No authoritative revenue-by-geography percentages were provided in the available excerpts, so a quantitative geographic revenue breakdown is not presented.
Share of the revenue the company reports by geography.
Risks
The company has no approved products and is dependent on clinical trial success and regulatory approvals, making outcomes highly sensitive to efficacy, safety, and trial execution in late-stage studies for 4D-150 and earlier-stage work for 4D-710. Competitive risk is significant because wet AMD/DME and cystic fibrosis have established therapies and well-funded competitors, which can raise the bar for differentiation and payer/physician switching. Manufacturing risk is elevated because gene therapies are complex to produce; production issues can delay trials, constrain supply, or increase costs. Partnering risk is also material: collaborations may not progress efficiently, and termination or underperformance by partners (e.g., in licensed territories) can reduce expected milestones/royalties and slow commercialization. Financing risk remains inherent given reliance on equity issuance and external funding to sustain multi-year development timelines.
- No approved products; limited operating history and late-stage development dependenceImpact: CriticalLikelihood: High
Business viability depends on successful completion of trials and approvals, which are uncertain and can materially change valuation and funding access.
- Gene therapy manufacturing is novel, complex and difficultImpact: HighLikelihood: Medium
Production problems can delay development/commercialization and limit supply, directly impacting timelines and costs.
- Collaboration agreements may not deliver efficient development or may terminateImpact: MediumLikelihood: Medium
Partner decisions and integration challenges can reduce expected milestones/royalties and slow regional commercialization.
Accounting
Judgemental itemsService completion is not always directly observable; estimates affect period expenses and comparability.
Impact: Can materially shift operating expense between quarters without changing program progress.
Recognition depends on contract terms and performance obligations; milestones may be constrained until probable.
Impact: Non-linear revenue/other income recognition and presentation can affect headline results.
Lease term and discount rate judgments affect right-of-use assets and lease liabilities.
Impact: Changes balance sheet leverage optics and operating expense profile.
Similar listed companies
Publicly listed companies with a comparable business focus.
MeiraGTx Holdings plc
MGTX · Biological Products, (No Diagnostic Substances)
MeiraGTx Holdings plc is a clinical-stage genetic medicines company developing adeno-associated virus (AAV) gene therapies for inherited retinal disease,…
C4 Therapeutics, Inc.
CCCC · Biological Products, (No Diagnostic Substances)
Maze Therapeutics, Inc.
MAZE · Biological Products, (No Diagnostic Substances)
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Voyager Therapeutics, Inc.
VYGR · Biological Products, (No Diagnostic Substances)
Outlook Therapeutics, Inc.
OTLK · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026